Paul E. Zorsky
Expertise in
39
conditions

Dr. Paul E. Zorsky

Hematology | Oncology
Trinity Health Of New England Medical Group – Glastonbury Cancer Center
31 Sycamore St, Ste 202, 
Glastonbury, CT 
Accepting New Patients
Offers Telehealth
Expertise in
39
conditions
Trinity Health Of New England Medical Group – Glastonbury Cancer Center
31 Sycamore St, Ste 202, 
Glastonbury, CT 

Overview

Paul Zorsky is a Hematologist and an Oncologist practicing medicine in Glastonbury, Connecticut.

Dr. Zorsky is highly rated in 39 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Chronic Lymphocytic Leukemia (CLL), Familial Colorectal Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Dr. Zorsky is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine, Medical Oncology , and American Board Of Internal Medicine, Hematology . He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 15 clinical trials. Dr. Zorsky is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in TX

Board Certifications

American Board Of Internal Medicine
American Board Of Internal Medicine, Medical Oncology
American Board Of Internal Medicine, Hematology

Fellowships

The George Washington University Medical Center, 1987

Hospital Affiliations

Cape Cod Hospital
Johnson Memorial Hospital
Falmouth Hospital
Bsa Hospital
St Francis Hospital & Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Trinity Health Of New England Medical Group – Glastonbury Cancer Center
31 Sycamore St, Ste 202, Glastonbury, CT 06033
Other Locations
Trinity Health Of New England Medical Group - Cancer Center
94 Woodland St, Hartford, CT 06105
Saint Francis Hospital and Medical Center - Hematology/Oncology
114 Woodland St, Hartford, CT 06105

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
ALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: June 05, 2026
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2026
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Denosumab for treatment of hypercalcemia of malignancy.
Denosumab for treatment of hypercalcemia of malignancy.
Journal: The Journal of clinical endocrinology and metabolism
Published: June 11, 2014
Similar Doctors
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Expertise in
11
conditions
Dr. Farzana D. Pashankar
Hematology | Oncology
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (33.2 miles away)
203-785-4081
Languages Spoken:
English
See accepted insurances

Farzana Pashankar is a Hematologist and an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pashankar is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Germ Cell Tumor, Teratoma of the Mediastinum, Testicular Yolk Sac Tumor, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
48
conditions
Dr. Todd J. Alekshun
Hematology | Oncology
Expertise in
48
conditions
Dr. Todd J. Alekshun
Hematology | Oncology
Referral may be required

Hartford Healthcare Medical Group

200 Merrow Rd, 
Tolland, CT 
 (16.2 miles away)
860-674-0088
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Todd Alekshun is a Hematologist and an Oncologist practicing medicine in Tolland, Connecticut. Dr. Alekshun is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Lung Adenocarcinoma.

Expertise in
6
conditions
Dr. Patrick T. Mcgann
Hematology | Oncology
Expertise in
6
conditions
Dr. Patrick T. Mcgann
Hematology | Oncology
Referral may be required

Rhode Island Hospital

593 Eddy St, 
Providence, RI 
 (61.7 miles away)
401-444-5241
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Patrick Mcgann is a Hematologist and an Oncologist practicing medicine in Providence, Rhode Island. Dr. Mcgann is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Anemia, Congenital Hemolytic Anemia, and Hemolytic Anemia. Dr. Mcgann is currently accepting new patients.

Frequently Asked Questions about Dr. Paul E. Zorsky

How do I make an appointment with Dr. Paul E. Zorsky?

You can book an appointment with Dr. Paul E. Zorsky by calling their office at 860-714-9170. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul E. Zorsky a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul E. Zorsky is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul E. Zorsky specialize in?

While Dr. Paul E. Zorsky is a Hematology, they have specific expertise in Lung Cancer, Chronic Lymphocytic Leukemia (CLL), and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Paul E. Zorsky participate in research or clinical trials?

Yes. Dr. Paul E. Zorsky has published 1 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Paul E. Zorsky's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul E. Zorsky accept my insurance?

Dr. Paul E. Zorsky accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 860-714-9170 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zorsky's expertise for a condition
ConditionClose
    View All 35 Advanced Conditions
    View All 90 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile